AACR 2023 - American Association of Cancer Research Annual Meeting 2023
Apr 14 - Apr 19, 2023 | OrlandoFLUS
LARVOL is not affiliated with American Association of Cancer Research Annual Meeting 2023 and all trademarks, logos, and brand names are property of their respective owners
Showing 531 abstracts linked to Trials
AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC
Discussion
Clinical Trials Plenary SessionIMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation
Discussion
Clinical Trials Plenary SessionA personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from the randomized, open-label Phase 2 mRNA-4157-P201/Keynote-942 trial
Discussion
Clinical Trials Plenary SessionS1512: High response rate with single agent anti-PD-1 in patients with metastatic desmoplastic melanoma
Discussion
Clinical Trials Plenary SessionFirst-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations
Discussion
Clinical Trials Plenary SessionPembrolizumab (pembro) in combination with gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC): Phase 3 KEYNOTE-966 study
Discussion
Clinical Trials Plenary SessionKEYMAKER-U02 substudy 02C: Neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma
Discussion
Clinical Trials Plenary SessionPhase I dose-escalation study of fractionated dose 225Ac J591 for metastatic castration resistant prostate cancer
Discussion
Clinical Trials Plenary SessionIntratumoral (IT) MEDI1191 + durvalumab (D): Update on the first-in-human study in advanced solid tumors
Discussion
Clinical Trials Plenary SessionPhase 2-3 trial of pegargiminase plus chemotherapy versus placebo plus chemotherapy in patients with non-epithelioid pleural mesothelioma
Discussion
Clinical Trials Plenary SessionPhase I/II study of the PARP inhibitor olaparib and ATR inhibitor ceralasertib in children with advanced malignancies: Arm N of the AcSé-ESMART trial
Discussion
Clinical Trials Plenary SessionClinical activity of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell cancer (HNSCC)
Discussion
Clinical Trials Plenary SessionA first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced myeloid malignancies
Discussion
Clinical Trials MinisymposiumSafety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in patients (pts) with solid tumors harboring DNA damage response (DDR) alterations
Discussion
Clinical Trials Plenary SessionClinical and translational findings of pemigatinib in previously treated solid tumors with activating FGFR1-3 alterations in the FIGHT-207 study